124 related articles for article (PubMed ID: 3318089)
1. Superficial bladder cancer treated by intravesical bacillus Calmette-Guerin or adriamycin: multicenter study interim report.
Khanna OP; Son DL; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Viek N; Friedmann M
Urology; 1987 Dec; 30(6):520-8. PubMed ID: 3318089
[TBL] [Abstract][Full Text] [Related]
2. Superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin: follow-up report.
Khanna OP; Son DL; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Viek N; Uhlman R
Urology; 1988 Apr; 31(4):287-93. PubMed ID: 3281363
[TBL] [Abstract][Full Text] [Related]
3. Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guerin or adriamycin. Results of long-term follow-up.
Khanna OP; Son DL; Son K; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Uhlman R
Urology; 1991 Sep; 38(3):271-9. PubMed ID: 1887543
[TBL] [Abstract][Full Text] [Related]
4. Multicenter study of superficial bladder cancer treated with intravesical bacillus Calmette-Guérin or adriamycin.
Khanna OP; Son DL; Mazer H; Read J; Nugent D; Cottone R; Heeg M; Rezvan M; Viek N; Uhlman R
Urology; 1990 Feb; 35(2):101-8. PubMed ID: 2407020
[TBL] [Abstract][Full Text] [Related]
5. Bacillus Calmette-Guerin versus doxorubicin versus thiotepa: a randomized prospective study in 202 patients with superficial bladder cancer.
Martínez-Piñeiro JA; Jiménez León J; Martínez-Piñeiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
J Urol; 1990 Mar; 143(3):502-6. PubMed ID: 2106041
[TBL] [Abstract][Full Text] [Related]
6. Intravesical therapy comparing BCG, adriamycin, and thiotepa in 200 patients with superficial bladder cancer: a randomized prospective study.
Martinez-Pineiro JA; Jimenez León J; Martinez-Pineiro L; Fiter L; Mosteiro JA; Navarro J; García Matres MJ; Cárcamo P
Prog Clin Biol Res; 1989; 310():237-52. PubMed ID: 2505269
[TBL] [Abstract][Full Text] [Related]
7. A trial of bacillus Calmette-Guérin versus adriamycin in superficial bladder cancer: a South-West Oncology Group Study.
Mori K; Lamm DL; Crawford ED
Urol Int; 1986; 41(4):254-9. PubMed ID: 3538593
[TBL] [Abstract][Full Text] [Related]
8. Risk of continued intravesical therapy and delayed cystectomy in BCG-refractory superficial bladder cancer: an investigational approach.
Luciani LG; Neulander E; Murphy WM; Wajsman Z
Urology; 2001 Sep; 58(3):376-9. PubMed ID: 11549484
[TBL] [Abstract][Full Text] [Related]
9. Long-term followup of patients treated with 1 or 2, 6-week courses of intravesical bacillus Calmette-Guerin: analysis of possible predictors of response free of tumor.
Coplen DE; Marcus MD; Myers JA; Ratliff TL; Catalona WJ
J Urol; 1990 Sep; 144(3):652-7. PubMed ID: 2388321
[TBL] [Abstract][Full Text] [Related]
10. Prospective randomized comparison of intravesical with percutaneous bacillus Calmette-Guerin versus intravesical bacillus Calmette-Guerin in superficial bladder cancer.
Lamm DL; DeHaven JI; Shriver J; Sarosdy MF
J Urol; 1991 Apr; 145(4):738-40. PubMed ID: 2005691
[TBL] [Abstract][Full Text] [Related]
11. Intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer: effect of bacillus Calmette-Guerin viability on treatment results.
Kelley DR; Ratliff TL; Catalona WJ; Shapiro A; Lage JM; Bauer WC; Haaff EO; Dresner SM
J Urol; 1985 Jul; 134(1):48-53. PubMed ID: 3892051
[TBL] [Abstract][Full Text] [Related]
12. Two courses of intravesical bacillus Calmette-Guerin for transitional cell carcinoma of the bladder.
Haaff EO; Dresner SM; Ratliff TL; Catalona WJ
J Urol; 1986 Oct; 136(4):820-4. PubMed ID: 3761438
[TBL] [Abstract][Full Text] [Related]
13. [Comparative study on prophylactic intravesical instillation of bacillus Calmette-Guerin (BCG) and adriamycin for superficial bladder cancers].
Tachibana M; Jitsukawa S; Iigaya T; Shibayama T; Baba S; Deguchi N; Hata M; Tazaki H
Nihon Hinyokika Gakkai Zasshi; 1989 Oct; 80(10):1459-65. PubMed ID: 2601218
[TBL] [Abstract][Full Text] [Related]
14. Intravesical 4'-epi-doxorubicin (epirubicin) versus bacillus Calmette-Guérin. A controlled prospective study on the prophylaxis of superficial bladder cancer.
Melekos MD; Chionis HS; Paranychianakis GS; Dauaher HH
Cancer; 1993 Sep; 72(5):1749-55. PubMed ID: 8348504
[TBL] [Abstract][Full Text] [Related]
15. Positive urinary cytology following a complete response to intravesical bacillus Calmette-Guerin therapy: pattern of recurrence.
Schwalb MD; Herr HW; Sogani PC; Russo P; Sheinfeld J; Fair WR
J Urol; 1994 Aug; 152(2 Pt 1):382-7. PubMed ID: 8015076
[TBL] [Abstract][Full Text] [Related]
16. Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
Chou R; Selph S; Buckley DI; Fu R; Griffin JC; Grusing S; Gore JL
J Urol; 2017 May; 197(5):1189-1199. PubMed ID: 28027868
[TBL] [Abstract][Full Text] [Related]
17. Intravesical bacillus Calmette-Guerin for superficial bladder cancer: experience with Danish 1331 strain.
Kamat MR; Kulkarni JN; Tongaonkar HB; Dalal AV
J Urol; 1994 Nov; 152(5 Pt 1):1424-8. PubMed ID: 7933175
[TBL] [Abstract][Full Text] [Related]
18. Long-term results of intravesical bacillus Calmette-Guerin therapy for superficial bladder cancer.
Sarosdy MF; Lamm DL
J Urol; 1989 Sep; 142(3):719-22. PubMed ID: 2769847
[TBL] [Abstract][Full Text] [Related]
19. Adverse impact of fibrin clot inhibitors on intravesical bacillus Calmette-Guerin therapy for superficial bladder tumors.
Hudson MA; Yuan JJ; Catalona WJ; Ratliff TL
J Urol; 1990 Dec; 144(6):1362-4. PubMed ID: 2231927
[TBL] [Abstract][Full Text] [Related]
20. Maintenance intravesical bacillus calmette-guerin for superficial transitional cell carcinoma of bladder. A retrospective study.
Schwalb DM; Addonizio JC; Camilleri J; Choudhury MS; Eshghi M
Urology; 1990 Sep; 36(3):222-5. PubMed ID: 2392811
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
